TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02251639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Brush Biopsy
Description: If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
Study: NCT04150887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered 75 mg/m\^2 subcutaneously or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally and the dose will ramp-up to 400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
Study: NCT01974739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochloorthiazide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03268421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fibromyalgia Integrative Training for Teens
Description: This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Graded Aerobic Exercise
Description: This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
Study: NCT03140358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate 0.01%
Description: Atropine 0.01%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate 0.01%
Description: Atropine 0.01%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04540510

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPEP therapy
Description: Oscillatory Positive Expiratory Pressure therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard pneumonia care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard pneumonia care
Study: NCT02550028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral levetiracetam
Description: Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous phenobarbital
Description: Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
Study: NCT04184687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofractures
Description: anterior cruciate ligament reconstruction will be performed in combination with the nanofractures for the treatment of cartilaginous lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no treatment cartilaginous lesions
Description: patient undergoing to the anterior cruciate ligament reconstruction without treatment of the cartilaginous lesions
Study: NCT02321293

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CurcuVIVA™
Description: 80 mg PO daily for 8 weeks with an option to reduce the dose based on individual tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor gefitinib (Iressa)
Description: 250 mg PO daily until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor erlotinib (Tarceva)
Description: 150 mg PO daily until progression
Study: NCT01231555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 100 mg once daily
Description: 1x100 mg capsule plus matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 200 mg once daily
Description: 2x100 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 600 mg once daily
Description: 1x600mg tablet
Study: NCT01126255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate 0.05%
Description: Topical application, once daily about 2 g, during 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 8%
Description: Topical application, once daily about 2 g, during 12 weeks
Study: NCT02550158

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Educational program EDU-MICI
Study: NCT02064088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group
Description: Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
Study: NCT03328884

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan Hydrochloride
Description: nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan hydrochloride, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered with a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy.
Study: NCT01097031

Intervention type: OTHER
Intervention: Infusion Intermittent
Study: NCT01049945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally or IV
Study: NCT04443595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-scopic pancreatic necrosectomy（DPN）
Description: Treatment of Acute Severe Pancreatitis with DPN
Study: NCT02248675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
Study: NCT02064088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group
Description: Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
Study: NCT01475448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long distance training
Description: Long distance training during four months, 3 times per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking training
Description: Walking training during four months, three times per week
Study: NCT02099981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoguanidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Study: NCT02248675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU
Description: Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
Study: NCT02911662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
Study: NCT03478748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental health education
Description: Anticipatory guidance given to mothers to promote their children's oral health.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental health education
Description: Anticipatory guidance given to mothers to promote their children's oral health.
Study: NCT03619408

Intervention type: DRUG
Intervention: Antacids
Description: Omeprazole 1 mg/kg/dose BID or Omeprazole 1mg/kg/dose BID plus Ranitidine 3 mg/kg/dose BID
Study: NCT03607097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary prevention program for drug related problems
Description: The interventions consists of three stages: 1) actions aimed at improving the chronic prescription of the patient, 2) actions aimed at improving the therapeutic adherence and 3) actions aimed at improving the assistance healthcare levels coordination
Study: NCT01033565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrol
Description: 5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
Study: NCT03101995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.~Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.~Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy.
Study: NCT03503578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Subjects will received sevoflurane for approximately 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Subjects will received sevoflurane and ketamine for approximately 60 minutes.
Study: NCT00076934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG2077 (CTLA4-IgG4m)
Description: RG2077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG2077 (CTLA4-IgG4m)
Description: RG2077
Study: NCT02137811

Intervention type: OTHER
Intervention: MICK Assay
Description: An automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells; the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells.
Study: NCT02994680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Three-burner LPG stove
Description: The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three-burner LPG stove
Description: The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.
Study: NCT01589783

Intervention type: OTHER
Intervention: completion of a questionnaire
Description: Completion of a questionnaire

Intervention type: OTHER
Intervention: completion of a questionnaire
Description: Completion of a questionnaire

Intervention type: OTHER
Intervention: Blood draw
Description: A subset of 100 women will have a blood test to measure Vitamin D levels
Study: NCT01247545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischaemic preconditioning
Description: Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
Study: NCT03527147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150 will be administered as a 1-hour intravenous (IV) infusion on Days 1, 3, 5 of Cycle 1, followed by weekly infusions (starting Day 8 of Cycle 1 and beyond).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib will be administered orally twice daily (bid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib will be administered orally twice daily (bid).
Study: NCT02994680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of LPG tanks
Description: One year supply of LPG fuel, in the form of delivery of 20 kg tank that holds 10 kg of LPG. Delivered to homes.
Study: NCT03527147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib will be administered orally twice daily (bid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib will be administered orally twice daily (bid).
Study: NCT02994680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vouchers for LPG tanks
Description: One year supply of LPG, in the form of vouchers to obtain a free LPG tanks from a distribution center. (Beginning one year after enrollment, for one year)
Study: NCT03527147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: AZD6738 will be administered orally twice daily (bid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4
Description: HU5F9-G4 infusions will be given on Weekly (Day 1, 8, 15, and 22) during the first two 28-day cycles, then will be given every two weeks (Day 1 and Day 15) in Cycle 3 and beyond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab infusions will be given Weekly starting on Day 8 (Day 8, 15, and 22) during the first 28-day cycle (4 weeks), then Day 1 of each 4 week cycle for Cycles 2-6. Starting with Cycle 8, Rituximab will be infused on Day 1 of every other cycle (every 8 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5153
Description: AZD5153 will be administered orally once per day (qd).
Study: NCT01765114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Formulation
Study: NCT00925054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG 0.001 mg/kg
Description: In Part 1, the planned starting dose levels is 0.001 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG 0.003 mg/kg
Description: In Part 1, the planned starting dose levels is 0.003 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG 0.01 mg/kg
Description: In Part 1, the planned starting dose levels is 0.01 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG 0.03 mg/kg
Description: In Part 1, the planned starting dose levels is 0.03 mg/kg
Study: NCT01772082

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet mediated walking program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet mediated walking program
Study: NCT00112229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: group 1
Description: Melan-A analog peptide + CpG + Montanide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: group 2
Description: Melan-A natural peptide + CpG + Montanide
Study: NCT01235598

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (CZP) 200 mg
Description: Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
Study: NCT00925054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG 0.1 mg/kg
Description: In Part 1, the planned starting dose levels is 0.1 mg/kg
Study: NCT00206583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Description: GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
Study: NCT01235598

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol (CZP) 200 mg
Description: Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
Study: NCT02550158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Educational program EDU-MICI
Study: NCT02435602

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NBI endoscopy
Description: GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
Study: NCT05099822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-97489
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT02167165

Intervention type: DRUG
Intervention: Digoxin Injection
Description: Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root
Study: NCT03128034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pretargeted Radioimmunotherapy
Description: Given 211\^At-BC8-B10 IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT00567762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Description: Opthalmic suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo eye drops
Study: NCT02203448

Intervention type: DEVICE
Intervention: Facet Wedge spinal system
Study: NCT01235598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (CZP) 400 mg
Description: Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
Study: NCT02435602

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lugol chromoendoscopy
Description: GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions \>= 5 mm diameter Pathologic examination of all biopsy tissue specimens
Study: NCT00112229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: group 3
Description: Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
Study: NCT01182038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BirthRite birthing seat
Description: Randomization takes place on admission to the labor ward when the participants are in active labor.Participants in this arm were to sit on the seat for 20 minute periods.After these 20 minutes, the participant should stand and mobilize during two to three contractions, before resuming the birth seat position. If progress of the descent of the fetal head was obvious the participant was not asked to mobilize.
Study: NCT01235598

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol (CZP) 400 mg
Description: Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
Study: NCT04989153

Intervention type: DIAGNOSTIC_TEST
Intervention: pepsinogen
Description: serum pepsinogen diagnosed gastric cancer and precanceous lesion

Intervention type: DIAGNOSTIC_TEST
Intervention: pepsinogen
Description: serum pepsinogen diagnosed gastric cancer and precanceous lesion
Study: NCT01638442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2797
Description: Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
Study: NCT01750814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3102C
Description: a single dose (0.5 mL) intramuscularly on the deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GC FLU inj.
Description: a single dose (0.5 mL) intramuscularly on the deltoid muscle
Study: NCT00112229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: group 4
Description: Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
Study: NCT02130713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Third generation fluoroquinolone
Description: Prulifloxacin 600 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplement + third generation fluoroquinolone
Description: Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg and prulifloxacin 600 mg